VTVTvTv Therapeutics Inc.

Nasdaq vtvtherapeutics.com


$ 15.12 $ -0.26 (-1.76 %)    

Monday, 09-Sep-2024 15:15:42 EDT
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 14.51
$ 15.66 x 100
$ 15.98 x 200
-- - --
$ 7.38 - $ 30.99
3,527
na
43.68M
$ 1.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-13-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-06-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-29-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-04-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 02-24-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-03-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-21-2020 12-31-2019 10-K
20 10-30-2019 09-30-2019 10-Q
21 07-31-2019 06-30-2019 10-Q
22 05-01-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-01-2017 09-30-2017 10-Q
29 08-02-2017 06-30-2017 10-Q
30 05-03-2017 03-31-2017 10-Q
31 02-24-2017 12-31-2016 10-K
32 11-03-2016 09-30-2016 10-Q
33 08-02-2016 06-30-2016 10-Q
34 05-13-2016 03-31-2016 10-Q
35 03-04-2016 12-31-2015 10-K
36 11-13-2015 09-30-2015 10-Q
37 09-14-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-puts-brake-on-vtv-therapeutics-diabetes-candidate-program-including-late-stage-study-stock-tanks

vTv Therapeutics faces a setback as the FDA places a clinical hold on its cadisegliatin program, impacting the CATT1 Phase 3 tr...

 vtv-therapeutics-announces-fda-has-placed-a-clinical-hold-on-the-cadisegliatin-clinical-program-which-includes-the-ongoing-catt1-phase-3-trial-in-type-1-diabetes

vTv Therapeutics Inc. (NASDAQ:VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small mole...

 vtv-therapeutics-screens-first-patient-in-catt1-pivotal-trial-evaluating-cadisegliatin-for-type-1-diabetes

Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthr...

 cantex-pharmaceuticals-receives-fda-orphan-drug-designation-for-azeliragon-for-the-treatment-of-pancreatic-cancer-azeliragon-was-discovered-by-and-originally-under-development-for-alzheimers-disease-by-vtv-therapeutics-which-cantex-licensed-worldwide-rights

 Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cance...

 vtv-therapeutics-q1-eps-117-up-from-240-yoy-sales-100m

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.17) per share. This is a 51.25 percent increase over losses of ...

 vtv-therapeutics-q4-eps-167-up-from-228-yoy

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.67) per share. This is a 26.75 percent increase over losses of ...

 sp-500-edges-lower-adt-posts-upbeat-earnings

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow t...

 why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION